Skip to main content
International
Ask us anything:
  • About
        • About We challenge convention so healthy can be possible
        • Our Story
          • Amneal at-a-glance
          • Our Founders
          • Our Milestones
        • Our Purpose & Commitments
        • Our Culture
          • Rise, Lead, Succeed
        • Our Leadership
          • Executive Leadership
          • Board of Directors
        • Our Locations
        • Responsibility
          • The Amneal Patient Assistance Programs
          • Product Donations
          • National & Local Philanthropy
          • Compliance and Ethics
        • Patient Community Connections
          • Our Commitment to Parkinson's
        • Awards & Recognition
  • Products
        • Products We create essential medicines
        • Our Portfolio
          • Biosciences
          • Generic Products
          • Specialty Products
          • Product Catalog
        • Quality
        • Drug Safety
          • Adverse Event Reporting
          • Medical Inquiries
          • Product Complaints
        • Operations
  • Research & Development
        • Research & Development We invest significantly in new product development
        • Generics R&D
        • Specialty R&D
          • Drug Delivery Technologies
        • Product Partnering
  • Investors
        • Investors Become an Informed Investor
  • News
  • Careers
        • Careers Help make healthy possible
        • Total Rewards
        • Search Our Career Opportunities
  • Contact
  • Customer Login
Amneal Pharmaceuticals
  • Investor Relations
  • Financial Reports
    • SEC Filings
    • Annual Reports
    • Quarterly & Other Reports
  • Events & Presentations
  • Stock Information
  • Corporate Governance
    • Policies
    • Executive Officers & Directors
    • Board Committees
  • Investor Resources
    • Analysts
    • Investor FAQ
    • Email Alerts
    • Information Request
    • RSS Feeds

Home Home  >  News  >  Press Releases

  • Investor Relations
  • Financial Reports
    • SEC Filings
    • Annual Reports
    • Quarterly & Other Reports
  • Events & Presentations
  • Stock Information
  • Corporate Governance
    • Policies
    • Executive Officers & Directors
    • Board Committees
  • Investor Resources
    • Analysts
    • Investor FAQ
    • Email Alerts
    • Information Request
    • RSS Feeds
Normal
Press Release RSS Feed (opens in new window)
Press release year list 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002
Dec 21, 2011
Amneal Launches Felbamate Oral Suspension
PDF format download (opens in new window)
Dec 21, 2011
Impax Pharmaceuticals Submits New Drug Application for IPX066 in Parkinson’s Disease
Dec 19, 2011
Impax Pharmaceuticals Initiates Phase IIb Trial of IPX159 in Restless Legs Syndrome
Dec 06, 2011
Amneal Announces Corporate Business Development Team
PDF format download (opens in new window)
Nov 23, 2011
Impax Laboratories to Present at the Piper Jaffray 23rd Annual Healthcare Conference
Nov 21, 2011
Amneal Launches Fluocinolone Acetonide Family For Skin And Ear Care
PDF format download (opens in new window)
Nov 21, 2011
Impax Laboratories Confirms Patent Challenge Relating to Generic FENTORA®
Nov 12, 2011
Chintu and Chirag Patel of Amneal Pharmaceuticals, LLC named Ernst & Young National Entrepreneur Of The Year® 2011 Life Sciences Award winners
PDF format download (opens in new window)
Nov 07, 2011
Impax Laboratories to Present at the Credit Suisse 2011 Healthcare Conference
Nov 01, 2011
Q3 2011 Impax Laboratories Inc Earnings Conference Call
Nov 01, 2011
Impax Laboratories Reports Third Quarter 2011 Financial Results
Oct 11, 2011
Impax Laboratories Schedules Conference Call and Webcast for Third Quarter 2011 Financial Results
Sep 22, 2011
Impax Laboratories to Present at the Jefferies Global Healthcare Conference in London
Sep 19, 2011
Generic Felbamate Now Available from Amneal
PDF format download (opens in new window)
Sep 14, 2011
Impax Laboratories to Present at the UBS Global Life Sciences Conference
Sep 13, 2011
Impax Laboratories Confirms Patent Challenge Relating to Generic JALYN(R) 0.5 mg/0.4 mg
Sep 06, 2011
Impax Laboratories Appoints Carole Ben-Maimon, M.D. President of Global Pharmaceuticals
Aug 31, 2011
Impax Laboratories Confirms Patent Challenge Relating to Generic NUEDEXTA(R) 20 mg/10 mg
Aug 15, 2011
Impax and GSK Announce Positive Topline Results of ASCEND-PD Phase III Study of IPX066 in Advanced Parkinson's Disease
Aug 02, 2011
Amneal Announces Four New Generic Drugs
PDF format download (opens in new window)
Aug 02, 2011
Impax Laboratories Reports Second Quarter 2011 Financial Results
Jul 26, 2011
Impax Pharmaceuticals Completes Enrollment in ASCEND-PD Phase III Trial of IPX066 in Parkinson's Disease
Jul 14, 2011
Impax Pharmaceuticals Awarded Michael J. Fox Foundation Grant for Ongoing Research of IPX066 for Parkinson's Disease
Jul 12, 2011
Impax Laboratories Schedules Conference Call and Webcast forSecond Quarter 2011 Financial Results
Jul 11, 2011
Amneal Announces Three New Generic Liquids
PDF format download (opens in new window)
Jul 05, 2011
Amneal Pharmaceuticals Executives Named Ernst & Young Entrepreneur of the Year® 2011 New Jersey Award Winners
PDF format download (opens in new window)
Jun 30, 2011
Impax Laboratories Announces Settlement of Litigation Relating to WELCHOL(R) Tablets and WELCHOL(R) Oral Suspension Products
Jun 21, 2011
Impax Laboratories Strengthens Leadership by Adding New Senior Vice Presidents for Global Operations and Global Quality Affairs
Jun 17, 2011
Impax Laboratories to Present at the Wells Fargo Securities Healthcare Conference
Jun 06, 2011
Impax Laboratories Provides an Update on Recent FDA Site Inspection
Jun 03, 2011
Impax Laboratories Confirms Patent Suit Relating to Generic Detrol(R) Immediate-Release 1 mg and 2 mg Tablets
Jun 03, 2011
Impax Laboratories to Present at theJefferies 2011 Global Healthcare Conference
Jun 01, 2011
Data on IPX066 ADVANCE-PD and APEX-PD Phase III Studies to be Presented at the International Congress of Parkinson's Disease and Movement Disorders Conference
May 31, 2011
HAYWARD, Calif., May 31, 2011 (BUSINESS WIRE) -- Impax Laboratories, Inc.(NASDAQ: IPXL) today announced that the Company will present at the Goldman Sachs 32nd Annual Global Healthcare Conference on Tuesday, June 7, at 1:20 p.m. PT. The conference will be
May 23, 2011
Amneal Receives Approval For Nitrofurantoin Oral Suspension – First Generic to Market
PDF format download (opens in new window)
May 11, 2011
Impax Laboratories Announces Voting Results from 2011 Annual Meeting of Stockholders
May 10, 2011
Impax Pharmaceuticals Provides an Update on Pipeline Candidate IPX159
May 06, 2011
Impax Laboratories to Present at the Bank of America Merrill Lynch 2011 Health Care Conference
May 06, 2011
Impax Laboratories Confirms Patent Suit Relating to Generic Concerta(R) 18, 27 and 36 mg Tablets
May 03, 2011
Impax Laboratories Reports First Quarter 2011 Financial Results
May 02, 2011
Impax Laboratories Appoints Mark A. Schlossberg as Senior Vice President and General Counsel
Apr 14, 2011
Impax Laboratories Schedules Conference Call and Webcast for First Quarter 2011 Financial Results
Apr 11, 2011
Impax Laboratories Confirms Patent Challenge Relating to OXYCONTIN(R) 10, 15, 20, 30, 40, 60, and 80 mg
Apr 08, 2011
Impax Laboratories Enters into Commercialization Agreement with Banner Pharmacaps
Apr 04, 2011
Impax Laboratories Confirms Patent Challenge Relating to DEXILANT(R) Delayed-ReleaseCapsules, 30 mg and 60 mg
Apr 01, 2011
Data on IPX066 APEX-PD Phase III Study for the Treatment of Early Parkinson’s Disease to be Presented at the American Academy of Neurology Conference
Mar 14, 2011
IPX066 Demonstrates Efficacy and Safety in ADVANCE-PD Phase III Study in Treatment of Advanced Parkinson's Disease
Mar 03, 2011
Amneal Receives FDA Approval For Indomethacin ER Capsules
PDF format download (opens in new window)
Mar 01, 2011
Impax Laboratories to Present at the Cowen & Co. 31st Annual Health Care Conference
Feb 25, 2011
Impax Laboratories to Present at the RBC Capital Markets' Healthcare Conference
Feb 24, 2011
Impax Laboratories Reports Fourth Quarter and Record Full Year 2010 Financial Results
Feb 18, 2011
Impax Laboratories Receives Final FDA Approval for Generic Adoxa(R) 150 mg Capsules
Jan 27, 2011
Impax Laboratories Schedules Conference Call and Webcast for Fourth Quarter and Full Year 2010 Financial Results
Jan 18, 2011
Impax Laboratories Corrects Inaccurate Information about Product Pipeline Opportunities Discussed in Several Financial Articles Circulated on the Internet
Jan 04, 2011
Impax Laboratories to Present at the J.P. Morgan Annual Healthcare Conference

Investor Faq

Get answers to important investor relation questions.

More

Investor Tools

  • Email Alerts
  • RSS Feeds
  • Email Page

IR Contact

Get answers to your investor relation questions.

More
  • Privacy Policy
  • Copyright & Legal Disclaimer
  • Web Accessibility
© Amneal Pharmaceuticals LLC.
All rights reserved.
Powered By Q4 Inc. 5.86.0.1 (opens in new window)
Back to top